There is a type of cholesterol-lowering drug that actually shrinks the fatty deposits in blood vessels that can cause heart attacks. The drug has no more side effects than a placebo, so it is safe to take for many years in people at high risk for heart problems.
See the scientific wording
In high-risk cardiovascular patients, treatment with PCSK9 inhibitors leads to significant regression of coronary atherosclerosis and exhibits a safety profile comparable to placebo, thereby supporting their long-term clinical use.
There's disagreement
The 4 studies we reviewed point in different directions — there's no clear consensus.
What the research says
4 studies reviewedSupporting (2)
Systematic Review With Meta-AnalysisMeta-analysis2025
This study shows that adding these drugs to statins helps stabilize or shrink artery plaques, but it doesn't tell us about side effects, so we can't say they're just as safe as a placebo.
Systematic Review With Meta-AnalysisMeta-analysis2026
This study shows that PCSK9 inhibitor drugs actually shrink and stabilize the fatty plaques in heart arteries, which is good for preventing heart attacks. It didn't look at side effects, but it shows the drugs work on the plaques themselves.
Contradicting (2)
Randomized Controlled TrialHuman2025
In this 12-week study, the drug evolocumab did not make the fatty plaques in the arteries shrink any more than a placebo did, so it doesn't support the idea that these drugs cause significant regression.
Case-Control StudyHuman2024
This study found that people taking PCSK9 inhibitors reported more infections like colds, flu, and stomach infections compared to other drugs, so the drug may not be as safe as the claim says.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
This medicine blocks a protein that stops the liver from removing bad cholesterol. So more bad cholesterol is removed from the blood, which means less cholesterol builds up in the heart arteries. This makes the plaques smaller and safer, so they don't cause heart attacks.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 2 supporting, 2 contradicting studies
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
There is a type of cholesterol-lowering drug that actually shrinks the fatty deposits in blood vessels that can cause heart attacks. The drug has no more side effects than a placebo, so it is safe to take for many years in people at high risk for heart problems.
Mechanism
2 studiesA medicine blocks a protein that stops the liver from cleaning cholesterol from the blood. This lowers bad cholesterol, which makes the plaques in the heart arteries shrink and become safer. Long-term use of this medicine does not cause more side effects than a sugar pill, so it can be safely used for years.
This medicine blocks a protein that stops the liver from removing bad cholesterol. So more bad cholesterol is removed from the blood, which means less cholesterol builds up in the heart arteries. This makes the plaques smaller and safer, so they don't cause heart attacks.
Alirocumab binds to the proprotein convertase subtilisin/kexin type 9 (PCSK9) enzyme, preventing it from attaching to LDL receptors on liver cells, which reduces the breakdown of these receptors.
Increased LDL receptor availability on liver cells enhances the removal of LDL cholesterol from the blood, leading to a substantial reduction in plasma LDL-C levels.
Lower plasma LDL-C levels reduce the concentration gradient that drives LDL particles into the arterial wall, limiting lipid accumulation in coronary atherosclerotic plaques.
Reduced lipid content within plaques decreases intraplaque inflammation and oxidative stress, modulating macrophage activity and reducing the secretion of matrix metalloproteinases.
Lower inflammation and lipid burden promote smooth muscle cell survival and collagen synthesis, leading to thickening of the fibrous cap and stabilization of the plaque, which ultimately results in plaque regression.
Evidence from Studies
Last searched 1mo ago
Supporting (2)
Community contributions welcome
This study shows that adding these drugs to statins helps stabilize or shrink artery plaques, but it doesn't tell us about side effects, so we can't say they're just as safe as a placebo.
Plaque regression and stabilization by proprotein convertase subtilisin/kexin type 9 inhibitors: a meta-analysis of intravascular imaging studies.
This study shows that PCSK9 inhibitor drugs actually shrink and stabilize the fatty plaques in heart arteries, which is good for preventing heart attacks. It didn't look at side effects, but it shows the drugs work on the plaques themselves.
Contradicting (2)
Community contributions welcome
Changes in non-culprit coronary lesions with PCSK9 inhibitors: the randomised, placebo-controlled FITTER trial.
In this 12-week study, the drug evolocumab did not make the fatty plaques in the arteries shrink any more than a placebo did, so it doesn't support the idea that these drugs cause significant regression.
This study found that people taking PCSK9 inhibitors reported more infections like colds, flu, and stomach infections compared to other drugs, so the drug may not be as safe as the claim says.
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Randomized Controlled Trials on PCSK9 Inhibitors and Coronary Atherosclerosis Regression
Comprehensive search for RCTs comparing PCSK9 inhibitors to placebo or other lipid-lowering therapies in high-risk cardiovascular patients, with outcomes including changes in coronary atheroma volume measured by intravascular ultrasound, and adverse event rates.
Double-Blind Placebo-Controlled Randomized Trial of a PCSK9 Inhibitor on Coronary Atherosclerosis Regression in High-Risk Patients
High-risk patients (e.g., those with established cardiovascular disease) randomly assigned to PCSK9 inhibitor or placebo for at least 12 months, with coronary atherosclerosis measured by IVUS at baseline and follow-up, and adverse events monitored.
Long-Term Prospective Cohort Study of Cardiovascular Outcomes and Safety in Patients Receiving PCSK9 Inhibitors
Enroll high-risk patients initiating PCSK9 inhibitors and a comparable group not receiving them, follow for 5+ years, measuring cardiovascular events, changes in atherosclerosis via imaging, and adverse events.
Case-Control Study to Evaluate Safety of PCSK9 Inhibitors: Comparing Adverse Event Rates in Users vs Non-Users
Select cases with specific adverse events (e.g., liver dysfunction, neurocognitive events) and controls without, compare prior exposure to PCSK9 inhibitors.